AU
UK
CA
US
IND
NZ
Last update at 2026-06-04T07:40:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
HUTCHMED (China) First Half 2025 Earnings: EPS: US$0.53 (vs US$0.03 in 1H 2024)
Sat 09 Aug 25, 07:34 AMHUTCHMED Reports 2025 Interim Results
Thu 07 Aug 25, 11:00 AMHUTCHMED (China) Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag
Thu 20 Mar 25, 12:43 PMHUTCHMED Reports 2024 Full Year Results and Provides Business Updates
Wed 19 Mar 25, 11:00 AMHUTCHMED (China) (LON:HCM) shareholders have earned a 3.7% CAGR over the last three years
Mon 10 Mar 25, 10:28 AM| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 521.47M | 45.36M | 105.60M | -410.42200M | -215.74000M |
| Minority interest | -0.82300M | -0.44100M | -0.31400M | -0.44900M | -27.60700M |
| Net income | 457.02M | 37.73M | 100.78M | -410.13900M | -227.65800M |
| Selling general administrative | 103.03M | 64.30M | 79.78M | 92.17M | 89.30M |
| Selling and marketing expenses | - | 48.62M | 53.39M | 43.93M | 37.83M |
| Gross profit | 212.22M | 281.32M | 151.55M | 115.31M | 97.89M |
| Reconciled depreciation | 13.31M | 12.34M | 8.21M | 8.66M | 7.19M |
| Ebit | -54.59439M | 1.76M | 59.07M | -409.77000M | -336.45800M |
| Ebitda | -41.28312M | 14.11M | 67.27M | -401.10600M | -329.26800M |
| Depreciation and amortization | 13.31M | 12.34M | 8.21M | 8.66M | 7.19M |
| Non operating income net other | - | - | - | - | - |
| Operating income | -54.59439M | -40.61000M | 18.38M | -409.77000M | -336.45800M |
| Other operating expenses | 603.24M | 670.81M | 819.62M | 834.10M | 684.45M |
| Interest expense | 2.87M | 2.87M | 0.76M | 0.65M | 0.59M |
| Tax provision | 63.61M | 7.19M | 4.51M | -0.28300M | 11.92M |
| Interest income | 49.88M | 40.08M | 36.15M | 9.60M | 2.08M |
| Net interest income | 47.01M | 37.21M | 35.39M | 8.95M | 1.48M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 63.63M | 7.19M | 4.51M | -0.28300M | 11.92M |
| Total revenue | 548.65M | 630.20M | 838.00M | 426.41M | 356.13M |
| Total operating expenses | 266.81M | 321.93M | 133.18M | 523.00M | 426.21M |
| Cost of revenue | 336.43M | 348.88M | 686.45M | 311.10M | 258.23M |
| Total other income expense net | 576.06M | 39.50M | 87.23M | -0.65200M | 120.72M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 457.73M | 38.17M | 101.09M | -360.38600M | -167.04100M |
| Net income applicable to common shares | - | - | - | -360.83500M | -194.64800M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 1750.71M | 1274.20M | 1279.77M | 1029.44M | 1372.66M |
| Intangible assets | 8.93M | 167.74M | 116.89M | - | 0.16M |
| Earning assets | - | - | - | - | - |
| Other current assets | 11.10M | 12.30M | 43.35M | 152.20M | 164.62M |
| Total liab | 501.15M | 502.34M | 536.39M | 392.57M | 333.15M |
| Total stockholder equity | 1236.24M | 759.93M | 730.54M | 610.37M | 986.89M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 210.69M | 306.19M | 329.04M | 282.79M | 17.19M |
| Common stock | 87.11M | 87.16M | 87.13M | 86.48M | 86.45M |
| Capital stock | 87.23M | 87.16M | 87.13M | 86.48M | 86.45M |
| Retained earnings | -378.12668M | -833.17200M | -870.86900M | -971.48100M | -610.32800M |
| Other liab | - | - | - | 15.37M | 14.33M |
| Good will | 3.11M | 2.99M | - | - | 3.38M |
| Other assets | - | - | - | 31.11M | 27.41M |
| Cash | 71.23M | 153.96M | 283.59M | 313.28M | 377.54M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 315.34M | 376.56M | 403.03M | 353.90M | 311.66M |
| Current deferred revenue | 31.37M | - | - | - | 226.38M |
| Net debt | 26.53M | -64.13800M | -197.45800M | -289.97800M | -343.47600M |
| Short term debt | 27.81M | 26.30M | 35.08M | - | 26.91M |
| Short long term debt | 24.97M | 23.37M | 31.16M | 0.00000M | 26.91M |
| Short long term debt total | 97.76M | 89.82M | 86.13M | 23.30M | 34.07M |
| Other stockholder equity | 1531.78M | 1517.53M | 1514.28M | 1495.37M | 1510.77M |
| Property plant equipment | - | - | - | 84.67M | 53.15M |
| Total current assets | 1565.20M | 1066.56M | 1096.84M | 839.89M | 1212.08M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | - | - | 610.37M | 983.35M |
| Short term investments | 1294.18M | 682.15M | 602.75M | 317.72M | 634.16M |
| Net receivables | 147.63M | 167.74M | 116.89M | 97.99M | 147.73M |
| Long term debt | 68.19M | 59.43M | 48.19M | 18.10M | 0.00000M |
| Inventory | 41.07M | 50.40M | 50.26M | 56.69M | 35.76M |
| Accounts payable | 45.47M | 42.52M | 36.33M | 71.11M | 41.18M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -4.52582M | -11.58500M | -8.16300M | - | - |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 11.14M | 697.59M | 30.13M | 333.46M | 639.00M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 185.50M | 207.64M | 182.93M | 189.56M | 160.59M |
| Capital lease obligations | 4.73M | 7.01M | 6.79M | 5.20M | 7.16M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -613.79300M | -96.06000M | -291.13600M | 296.59M | -275.49400M |
| Change to liabilities | - | - | - | 30.32M | 20.64M |
| Total cashflows from investing activities | -29.41721M | -96.06000M | -291.13600M | 296.59M | -306.32000M |
| Net borrowings | 6.26M | 5.61M | 61.70M | -9.17000M | -0.57900M |
| Total cash from financing activities | 7.84M | -30.66700M | 48.66M | -82.76300M | 650.03M |
| Change to operating activities | - | - | - | 64.04M | 63.46M |
| Net income | 457.02M | 38.17M | 101.09M | -360.38600M | -167.04100M |
| Change in cash | -94.27730M | -129.63100M | -29.68900M | -64.26400M | 141.91M |
| Begin period cash flow | 165.51M | 283.59M | 313.28M | 377.54M | 235.63M |
| End period cash flow | 71.23M | 153.96M | 283.59M | 313.28M | 377.54M |
| Total cash from operating activities | -64.67286M | 0.50M | 219.26M | -268.59900M | -204.22300M |
| Issuance of capital stock | 1.58M | 0.79M | 5.09M | 0.17M | 717.32M |
| Depreciation | 13.31M | 12.34M | 8.21M | 8.66M | 7.19M |
| Other cashflows from investing activities | - | 1.28M | 29.50M | - | -15.00000M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | 9.54M | -0.77200M | 4.13M | -21.21300M | -16.00200M |
| Change to account receivables | 28.87M | -41.57300M | -21.33600M | -14.45100M | -35.63400M |
| Sale purchase of stock | 0.00000M | -36.06400M | -9.07100M | -48.08400M | -27.30900M |
| Other cashflows from financing activities | - | -1.00000M | -9.06800M | -7.93000M | -39.98200M |
| Change to netincome | - | - | - | 24.85M | -49.26700M |
| Capital expenditures | 14.15M | 17.93M | 32.61M | 36.66M | 16.76M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | -60.87893M | -62.16900M | 71.15M | 58.70M | 32.46M |
| Stock based compensation | 15.29M | 21.61M | 36.60M | 30.59M | 41.99M |
| Other non cash items | -474.12626M | -9.45400M | 1.60M | -6.16700M | -3.68300M |
| Free cash flow | -78.82433M | -17.43600M | 186.65M | -305.26300M | -220.97900M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
| Company | Change (GBX) | Price (GBX) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| HCM HUTCHMED China Ltd |
-5.0 2.86% | 170.00 | 5.38 | 19.30 | 3.37 | 2.02 | 2.25 | 2.40 |
| HLN Haleon PLC |
3.20 1.00% | 324.40 | 20.24 | 18.94 | 2.95 | 2.02 | 3.68 | 14.19 |
| HIK Hikma Pharmaceuticals PLC |
24.00 1.69% | 1440.00 | 9.73 | 9.03 | 0.85 | 1.45 | 1.53 | 6.07 |
| AGY Allergy Therapeutics |
0.20 2.30% | 8.90 | - | 106.38 | 11.72 | 159.47 | 12.12 | -4.1496 |
| ANCR Animalcare Group Plc |
0.56 0.17% | 332.06 | 61.50 | 16.92 | 2.09 | 1.43 | 2.13 | 14.48 |
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to treat pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
Cheung Kong Center, Hong Kong, Hong Kong
| Name | Title | Year Born |
|---|---|---|
| Mr. Chi Keung To ACGI, B.Sc., BSc, M.B.A., MBA | Exec. Chairman | 1952 |
| Dr. Weiguo Su B.Sc., Ph.D. | CEO, Chief Scientific Officer & Exec. Director | 1957 |
| Mr. Chig Fung Cheng BEc, CA | CFO & Exec. Director | 1967 |
| Ms. Edith Shih C.S., CGP, FCS, M.A., P.E., BSE, EdM, Solicito | Company Sec. & Non-Exec. Director | 1952 |
| Dr. Karen Jane Atkin | Exec. VP & COO | 1966 |
| Mr. Kin Hung Lee M.B.A. | Sr. VP of Corp. Fin. & Devel. | 1977 |
| Mr. Charles George Rupert Nixon | Group Gen. Counsel | 1970 |
| Ms. Selina Zhang | Sr. VP of Global HR | NA |
| Dr. Qingmei Wang Ph.D. | Sr. VP of Bus. Devel. & Strategic Alliances | 1963 |
| Mr. Hong Chen | Sr. VP & Chief Commercial Officer- China | 1970 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...